Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study-Reference-Cited by-同舟云学术

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

Published:2020-03 Issue:3 Volume:2 Page:e142-e152
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Fisher Benjamin A,Szanto Antonia,Ng Wan-Fai,Bombardieri Michele,Posch Maximilian G,Papas Athena S,Farag Arwa M,Daikeler Thomas,Bannert Bettina,Kyburz Diego,Kivitz Alan J,Carsons Steven E,Isenberg David A,Barone Francesca,Bowman Simon J,Espié Pascal,Floch David,Dupuy Cyrielle,Ren Xiaohui,Faerber Petra M,Wright Andrew M,Hockey Hans-Ulrich,Rotte Michael,Milojevic Julie,Avrameas Alexandre,Valentin Marie-Anne,Rush James S,Gergely Peter

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference30 articles.

1. Primary Sjögren's syndrome;Mariette;N Engl J Med,2018

2. A comprehensive review of autoantibodies in primary Sjögren's syndrome: clinical phenotypes and regulatory mechanisms;Kyriakidis;J Autoimmun,2014

3. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome;Stott;J Clin Invest,1998

4. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome;Salomonsson;Arthritis Rheum,2003

5. The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review;Risselada;Semin Arthritis Rheum,2013

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Sjögren disease syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Pathogenesis of Sjögren syndrome;Dubois' Lupus Erythematosus and Related Syndromes;2025

3. Precision medicine in Sjögren's disease;The Lancet Rheumatology;2024-09

4. Sjögren's disease: a new era for clinical trials?;The Lancet;2024-08

5. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study;The Lancet;2024-08